L.A. Naleskina, N.Y. Lukianova, L.M. Kunska, V.F. Chekhun
R.E.Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine



Summary. Literature data analysis proved that the expression of bone tissue remodeling proteins (osteopontin, osteonectin, BMP-7) and their impact on metastasis, particularly into bone tissue, are carried out due to direct or indirect involvement of molecular profile markers, namely steroid hormone receptors (estrogens, progesterone) and Ki-67, E-cadherin, N-cadherin, CD-44 adhesion molecules. With the appearance of malignant neoplasm, the absence or expression of each of these markers of the molecular profile reflects the orientation of the tumor process, and therefore its malignancy, and thereby determines the degree of involvement in metastatic spread of tumor cells to bones. Therefore, the most objective solution to the issue of determining the prognosis of the disease and justified treatment of patients with breast cancer can be accepted only at complex application of modern biomarkers of bone tissue remodeling, as well as a panel of markers of the molecular profi   of neoplasms.



  1. Ahmad E, Ali A, Hamdard J, Kumar Molecular markers in cancer. Clin Chim Acta 2022; 532 (3): 95–114. doi: 10. 1016/j.cca.2022.05.029.
  2. D’Oronzo S, Brown J, Coleman The role of biomarkers in the management of bone-homing malignancies. J Bone Oncol 2017; 9: 1–9. doi: 10.1016/j.jbo.2017.09.001.
  3. Alarcón-Zendejas AP, Scavuzzo A, Jiménez-Ríos MA, et al. The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intel- ligence Prostate Cancer and Prostatic Diseases 2022; 25: 431–43.
  4. Khongsti K, Das Osteopontin and breast cancer metastasis: Possible role of genistein on the regulation of osteopon- tin. Phytomedicine Plus 2021; 1 (4): 00138. https://doi. org/10.1016/j.phyplu.2021.100138.
  5. Hao C, Wang Z, Gu Y, et al. Prognostic value of osteopon- tin splice variant-c expression in breast cancers: A meta- Biomed Res Int 2016; 2016: 7310694. doi: 10.1155/ 2016/7310694.
  6. Lopergolo A, Zaffaroni Biomolecular markers of outcome prediction in prostate cancer. Cancer 2009; 115 (13 Suppl): 3058–67. doi: 10.1002/cncr.24346.
  7. Mohanty SS, Sahoo SR, Padhy Role of hormone recep- tors and HER2 as prospective molecular markers for breast cancer: An update. Genes Dis 2022; 9 (3): 648–58. doi: 10.1016/j.gendis.2020.12.005.
  8. Quinn DI, Henshall SM, Sutherland Molecular markers of prostate cancer outcome. Eur J Cancer 2005; 41 (6): 858–87. doi:  10.1016/j.ejca.2004.12.035.
  9. Wei R, Wong JPC, Kwok Osteopontin — a promising biomarker for cancer therapy. J Cancer 2017; 8 (12): 2173– 83. doi: 10.7150/jca.20480.
  10. Kuo MC, Kothari AN, Kuo PC, Mi Cancer stemness in bone marrow micrometastases of human breast cancer. Sur- gery 2018; 163 (2):  330–5. doi: 10.1016/j.surg.2017.07. 027.
  11. Kim YW, Park YK, Lee J., et al. Expression of osteopontin and osteonectin in breast Journal of Korean Medical Science 1998; 13 (6): 652–7. doi: jkms.1998.13.6.652
  12. Zhao H, Chen Q, Alam A, et al. The role of osteopontin in the progression of solid organ Cell Death Dis 2018; 9 (3): 356. doi: 10.1038/s41419-018-0391-6.
  13. Khogaly RSE, Abdrabo AA, Hussein WA, et al. Association between osteopontin and hormone receptor  status among breast cancer patients. PJMHS 2022; 16 (12): 447. doi:
  14. Rucci N, Teti A. Osteomimicry: How the seed grows in the soil. Calcif Tissue Int 2018; 102: 131–40. doi: 10.1007/ s00223-017-0365-1.
  15. Pang X, Gong K, Zhang X, et al. Osteopontin as a multifacet- ed driver of bone metastasis and drug Pharmacol Res 2019; 144: 235–44. doi: 10.1016/j.phrs.2019.04.030.
  16. Shevde L, Das S, Clark D, Samant Osteopontin: An ef- fector and an effect of tumor metastasis. Curr Mol Med 2010; 10: 71–81. doi: 10.2174/156652410791065381.
  17. Yu Q, Stamenkovic Localization of matrix metalloprotei- nase 9 to the cell surface provides a mechanism for CD44- mediated tumor invasion. Genes Dev 1999; 13: 35–48.
  18. Ponzetti M, Rucci Switching homes: how cancer moves to bone. Int J Mol Sci 2020; 21 (11): 4124. doi: 10.3390/ ij  1114124.
  19. Wood SL, Brown Personal medicine and bone me- tastases: biomarkers, micro-RNAs and bone metastases. Cancers (Basel) 2020; 12 (8): 2109. doi: 10.3390/cancers 12082109.
  20. Xu H, Niu M, Yuan X, et al. CD44 as a tumor biomarker and therapeutic Exp Hematol Oncol 2020; 9 (1): 36. doi: 10.1186/s40164-020-00192-0.
  21. Mesrati MH, Syafruddin SE, Mohtar MA, Syahir A. CD44: a multifunctional mediator of cancer progress Biomo- lecules 2021; 11 (12): 1850; doi: 10.3390/biom11121850.
  22. Wang Z, Zhao K, Hackert T, Zöller CD44/CD44v6 a reliable companion in cancer-initiating cell  maintenance and tumor progression. Front Cell Dev Biol 2018; 6: 97. doi:  10.3389/fcell.2018.00097.
  23. Kariya Y. Osteopontin in cancer: mechanisms and therapeu- tic t Int J Transl Med 2022; 2: 419–47. https://doi. org/10.3390/ij
  24. Bhadresha KP, Patel M, Jain NK, Rawal A predic- tive biomarker panel for bone metastases: liquid biopsy approach. J Bone Oncol 2021; 29: 100374. doi: 10.1016/j. jbo.2021.100374.
  25. Elbaiomy MA, ElGhonemy MS, Elhelaly R, Elzehery R. Osteopontin level and promoter polymorphism is associated with aggressiveness in breast Ann Oncol 2018; 29 (9): ix15.
  26. Ruan Y, Chen L, Xie D, et This article is part of the re- search topic mechanisms of cell adhesion molecules in endocrine-related cancers: a concise outlook. Front Endo- crinol (Lausanne) 2022; 13: 865436. doi: 10.3389/fendo. 2022.865436.
  27. Murray N Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management. Biol Res 2018; 51 (1): 32. doi: 10.1186/s40659-018-0180-9.
  28. Kowalski PJ, Rubin MA, Kleer E-cadherin expression in primary carcinomas of breast and its distant metasta- sis. Breast Cancer Res 2003; 5: R217–22. doi: 10.1186/ bcr651.
  29. Wells A, Yates C, Shepard E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis 2008; 25 (6): 621–8. doi: 10.1007/s10585-008- 9167-1.
  30. Graff JR, Gabrielson E, Fujii H, et al. Methylation patterns of the E-cadherin 5′CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progress J Biol Chem 2000; 275 (4): 2727–32. doi: 10.1074/jbc.275.4.2727.
  31. Hajra KM, Chen DY, Fearon The SLUG zinc finger protein represses E-cadherin in breast cancer. Cancer Res 2002; 62 (6): 1613–8.
  32. Nam JS, Ino Y, Kanai Y, et al. 5-aza-2′-deoxycytidine restores the E-cadherin system in E-cadherin silenced cancer cells and reduces cancer metast Clin Exp Metastasis 2004; 21 (1): 49–56. doi: 10.1023/b:clin.0000017180.19881.c1.
  33. Shurin Osteopontin controls immunosuppression in the tumor microenvironment. J Clin Invest 2018; 128 (12): 5209–12. doi: 10.1172/JCI124918.
  34. Walaszek K, Lower EE, Ziolkowski P, Weber GF. Breast can- cer risk in premalignant lesions: osteopontin splice variants indicate progno Br J Cancer 2018; 119 (10): 1259–66. doi: 10.1038/s41416-018-0228-1.
  35. Santisteban M, Reynolds C, Barr Fritcher EG, et al. Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplas Breast Cancer Res Treat 2010; 121 (2): 431–37. doi: 10.1007/s10549-009-0534-7.
  36. Weber GF. Crossroads: the role of biomarkers in the manage- ment of lumps in the breas Oncotarget 2023; 14: 358–62. doi: 10.18632/oncotarget.28402.
  37. Shi S, Ma H-Y, Han X-Y, et al. Prognostic significance of SPARC expression in breast cancer: a meta-analysis and bioinformatics Biomed Res Int 2022; 2022: doi: 10.1155/2022/8600419.
  38. Guo W, Zhang M, Chen Y, Guo The clinical signifi ance of secreted protein acidic and rich in cysteine expression in breast cancer tissue and its association with prognosis. J Cancer Res Ther 2017; 13 (5): 833–6. doi: 10.4103/jcrt. JCRT_424_17.
  39. Kim NI, Kim GE, Lee JS, Park In phyllodes tumors of the breast expression of SPARC (osteonectin/BM40) mRNA by in situ hybridization correlates with protein ex- pression by immunohistochemistry and is associated with tumor progression.Virchows Arch 2017; 470 (1): 91–8. doi: 10.1007/s00428-016-2048-0.
  40. Alcaraz LB, Mallavialle A, Mollevi C, et al. SPARC in can- cer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity. Int J Cancer 2023; 152 (6): 1243–58. doi: 11002/ij  4345.
  41. Kim NI, Kim G-E, Park MH, et al. Up-regulation of SPARC is associated with tumor progression and epithelial SPARC expression is correlated with poor survival and MMP-2 expression in patients with breast Int J Clin Exp Pathol 2017; 10 (3): 2675–88. www.ij /ISSN:1936- 2625/IJ 47490.
  42. López-Moncada F, Torres MJ, Castellón EA, Contreras Secreted protein acidic and rich in cysteine (SPARC) in- duces epithelial-mesenchymal transition, enhancing migra- tion and invasion, and is associated with high Gleason score in prostate cancer. Asian J Androl 2019; 21 (6): 557–64. doi: 10.4103/aja.aja_23_19.
  43. Ma J, Gao S, Xie X, et al. SPARC inhibits breast cancer bone metastasis and may be a clinical therapeutic targe Oncol Lett 2017; 14 (5): 5876–82. doi: 10.3892/ol.2017. 6925.
  44. Lepucki A, Orlińska K, Mielczarek-Palacz A, et al. The role of extracellular matrix proteins in breast Clin Med 2022; 11 (5): 1250. doi: 10.3390/jcm11051250.
  45. Wyatt AW, Osborne RJ, Stewart H, et al. Bone morpho- genetic protein 7 (BMP7) mutations are associated with variable ocular, brain, ear, palate, and skeletal anomalies. Human Mutation 2010; 31 (7): 781–87. doi: 1002/hu- mu.21280.
  46. Pulido C, Vendrell I, Ferreira AR, et al. Bone metastasis risk factors in breast Ecancermedicalscience 2017; 11: 715. doi:  10.3332/ecancer.2017.715
  47. Alarmo EL, Korhonen T, Kuukasjärvi T, et al. Bone morpho- genetic protein 7 expression associates with bone metastasis in breast carcinoma Ann Oncol 2008; 19 (2): 308–14. doi: 10.1093/annonc/mdm453.
  48. Schwalbe M, Sänger J, Eggers R, et al. Differential expres- sion and regulation of bone morphogenetic protein 7 in breast cancer. Int J Oncol 2003; 23 (1): 89–95. https://
  49. Katsuta E, Maawy AA, Yan L, Takabe K. High expression of bone morphogenetic protein (BMP) 6 and BMP7 are associated with higher immune cell infi  tion and bet- ter survival in estrogen receptor-positive breast cance Oncol Rep 2019; 42 (4): 1413–21. doi: 10.3892/or.2019. 7275.
  50. Bach DH, Park HJ, Lee SK. The dual role of bone morpho- genetic proteins in Mol Ther Oncol 2018; 8: 1–13. doi: 10.1016/j.omto.2017.10.002.
  51. Lukianova N, Zadvornyi T, Kashuba E, et al. Expression of markers of bone tissue remodeling in breast cancer and prostate cancer cells in v Exp Oncol 2022; 44 (1): 39–46. doi: 10.32471/exp-oncology.2312-8852.vol-44-no- 1.17354.

No comments » Add comment